Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwAL 2022 | New frontiers in ALL – MRD for clinical practice

Robin Foà and Sabina Chiaretti • 29 Sep 2022
iwAL 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab

Sabina Chiaretti, MD, PhD, and Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discuss the use of measurable residual disease (MRD) in clinical practice for acute lymphoblastic leukemia (ALL). This discussion took place at the 4th International Workshop on Acute Leukemias (iwAL), which was held in Nice, France, on 16 – 18 September 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Robin Foà

Novel treatment strategies in ALL
Nicholas Short et al. • 29 Sep 2022
Considerations for the implementation of novel therapies into ALL clinical practice 4:41
Considerations for the implementation of novel therapies into ALL clinical practice
Robin Foà • 15 Apr 2024
Are transplantation and chemotherapy still necessary for all patients with Ph+ ALL? 5:14
Are transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
The José Carreras award and a history of immunotherapy in Ph+ ALL 8:11
The José Carreras award and a history of immunotherapy in Ph+ ALL
Robin Foà • 11 Jun 2023

More from Sabina Chiaretti

Ponatinib plus blinatumomab versus imatinib and chemotherapy in Ph+ ALL: the GIMEMA ALL2820 trial 4:52
Ponatinib plus blinatumomab versus imatinib and chemotherapy in Ph+ ALL: the GIMEMA ALL2820 trial
Sabina Chiaretti • 5 Dec 2025
A retrospective study of asciminib for R/R Ph+ ALL and LBC-CML 1:58
A retrospective study of asciminib for R/R Ph+ ALL and LBC-CML
Sabina Chiaretti • 5 Dec 2025
ALL over the years
Dieter Hoelzer et al. • 29 Sep 2022
T-cell engagers and treating relapsed ALL
Bijal Shah et al. • 29 Sep 2022

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals